Apimeds Pharmaceuticals Us, Inc To Start Trading Tomorrow

Apimeds Pharmaceuticals US, Inc APUS IPO will take place February, 21 on the NYSE exchange under the ticker APUS.

The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on August 20, 2025.

See also: Benzinga IPO Calendar

About Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that is in the process of developing Apitox, a proprietary intradermally administered bee venom-based toxin, primary focus is to advance Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis ("OA") and, eventually, multiple sclerosis ("MS").

See also: Benzinga's Most Shorted Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.